Old Web
English
Sign In
Acemap
>
authorDetail
>
Nisha Jain
Nisha Jain
Takeda Pharmaceutical Company
Medicine
ADAMTS13
Recombinant DNA
Pathogenesis
Thrombosis
4
Papers
13
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Recombinant ADAMTS13 reduces abnormally up-regulated von Willebrand factor in plasma from patients with severe COVID-19.
2021
Thrombosis Research
Peter L. Turecek
Rachel C Peck
Savita Rangarajan
Christopher Reilly-Stitt
Michael Laffan
Rashid S. Kazmi
Izabela James
Ahilanandan Dushianthan
Gerald Schrenk
Herbert Gritsch
Bruce M. Ewenstein
Bjorn L Mellgard
Wolfhard Erdlenbruch
Nisha Jain
Nikolaus B. Binder
Andrew D Mumford
Show All
Source
Cite
Save
Citations (13)
Recombinant ADAMTS13 for Patients with Severe Congenital Thrombotic Thrombocytopenic Purpura: Design of a Phase 3b Open-Label Continuation Study of Prophylactic and on-Demand Treatment
2021
Blood
Nisha Jain
Cecilia Marquez
Leah Martell
Show All
Source
Cite
Save
Citations (0)
Recombinant ADAMTS13 for Patients with Sickle Cell Disease: Design of a Phase 1 Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study
2021
Blood
Parth Patwari
Van Anh (Vika) Nguyen
Indranil Bhattacharya
Nisha Jain
Show All
Source
Cite
Save
Citations (0)
Recombinant Porcine Factor VIII in Patients with Congenital Hemophilia a with Inhibitors Undergoing Surgery: Phase 3, Multicenter, Single Arm, Open-Label Study
2021
Blood
Christian Pfrepper
Paolo Radossi
Jerzy Windyga
Kaan Kavakli
Roger E.G. Schutgens
Nazan Sarper
Jovanna Baptista
Kayode Badejo
Bruce Ewenstein
Nisha Jain
Show All
Source
Cite
Save
Citations (0)
1